by David Eyre | Mar 4, 2026 | US & International
Background REGENXBIO and the Trustees of the University of Pennsylvania sued Sarepta for infringing multiple claims of U.S. Patent No. 10,526,617, which is directed to cultured host cells containing a recombinant nucleic acid molecule encoding an AAV capsid sequence...
by David Eyre | Feb 18, 2026 | US & International
This case is important because it allows the Supreme Court to define the point of balance between enforcement of patent rights for medical uses and the competition in the market place for generic pharmaceuticals. Consequently, the ruling of the Supreme Court will have...
by Luke Pettit | Jan 15, 2026 | UPC
Background The UPC Court of Appeal’s decision in Otec v. Steros provides an interesting insight into claim interpretation and the constraints on relying on post-filing experimental evidence at the UPC. The case, UPC Court of Appeal decision 579/2025, arose from a...
by David Eyre | Dec 22, 2025 | EPO
Background Under G 1/92, a product on the market was not considered “available” as prior art under Article 54(2) EPC if the skilled person could not reproduce it without undue burden. This created a peculiar legal fiction: a product could be purchased yet legally...
by Carolyn Haywood | Oct 28, 2025 | US & International
In district court litigation, patents can be challenged on any ground, and challenges may be based on any kind of prior art recognised by the patent statutes. Inter partes review (IPR) proceedings are, however, different. They are administrative proceedings in which...
Recent Comments